Use in pregnancy is not recommended. There are no human data on use during pregnancy to assess the risk of adverse maternal or fetal outcomes. Based on animal data, the drug may cause fetal harm. During organogenesis, embryofetal lethality and teratogenicity were observed in rats, and reduced fetal weight in rats and rabbits. Breastfeeding is not recommended during treatment due to potential adverse reactions in the infant. There are no data on the presence of the drug or its metabolites in human milk. It is not known whether it has an effect on the infant or on milk production. Use in people under 18 years of age can affect bone and cartilage growth. In rats, bone and cartilage toxicity was observed after repeated dosing.
Molnupiravir
Balapiravir
Odalasvir
Saquinavir
Remdesivir
Coronavir
Favipiravir
Maribavir